Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
|
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [1] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Agnieszka Koper
    Sławomir Wileński
    Paulina Śledzińska
    Marek Bebyn
    Krzysztof Koper
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10867 - 10877
  • [2] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Martinez-Lago, Nieves
    Calleja Chucla, Teresa
    Alonso De Castro, Beatriz
    Varela Ponte, Rafael
    Reboredo Rendo, Cristina
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Grana Suarez, Begona
    de la Camara Gomez, Juan
    Busto Fernandez, Fernando
    Mateos Salvador, Maria
    Reboredo Lopez, Margarita
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [3] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Martinez-Perez, Julia
    Carmen Riesco-Martinez, M.
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650
  • [4] Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib
    Hsiao, Kai-Yuan
    Chen, Hsin-Pao
    Rau, Kun-Ming
    Liu, Kuang-Wen
    Shia, Ben-Chang
    Chang, Wei-Shan
    Liang, Hao-Yun
    Hsieh, Meng-Che
    ONCOLOGIST, 2024, 29 (12): : e1669 - e1679
  • [5] Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Narita, Yukiya
    Tsushima, Takahiro
    Ishihara, Makoto
    Todaka, Akiko
    Tanaka, Tsutomu
    Yokota, Tomoya
    Kadowaki, Shigenori
    Machida, Nozomu
    Ura, Takashi
    Fukutomi, Akira
    Ando, Masashi
    Onozawa, Yusuke
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Mori, Keita
    Yamazaki, Kentaro
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E15 - E22
  • [6] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [7] Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
    Kamiimabeppu, Daisaku
    Osumi, Hiroki
    Shinozaki, Eiji
    Ooki, Akira
    Wakatsuki, Takeru
    Yoshino, Koichiro
    Sato, Taro
    Nakayama, Izuma
    Ogura, Mariko
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [8] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
    Victorino, Ana Paula Ornellas S.
    Meton, Fernando
    Mardegan, Luciana
    Festa, Juliana
    Piranda, Diogo N.
    Araujo, Kelly Borges
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
  • [9] Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia
    Price, Timothy
    Burge, Matthew
    Chantrill, Lorraine
    Gibbs, Peter
    Pavlakis, Nick
    Shapiro, Jeremy
    Sjoquist, Katrin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 12
  • [10] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Fujimoto, Yoshiaki
    Nakanishi, Ryota
    Nukatsuka, Mamoru
    Matsuoka, Kazuaki
    Ando, Koji
    Wakasa, Takeshi
    Kitao, Hiroyuki
    Oki, Eiji
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (06) : 1029 - 1038